# A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

> **NCT01484275** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 85 (actual)

## Conditions studied

- High-risk Smoldering Multiple Myeloma

## Interventions

- **DRUG:** Siltuximab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01484275
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-01
- **Primary completion:** 2015-05-12
- **Final completion:** 2019-08-21
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01484275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01484275, "A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01484275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*